News summary

VectorY raises $83.5m to push its ALS antibody

Source: Longevity Technology • Published: 20 Nov 2026, 17:40

Summarized by Masters of Longevity from Longevity Technology.

VectorY closed $83.5 million to fund an expanded ALS trial and brain‑disease programs.

VectorY raises $83.5m to push its ALS antibody
Key Takeaways
  • VectorY raised $83.5 million to fund development.
  • The company is targeting pathological TDP‑43 aggregates in ALS.
  • Proceeds will fund an expanded ALS trial and pipeline.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.